Henry Schein, the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced it has completed the acquisition of a majority ownership stake of Biotech Dental S.A.S., a rapidly growing provider of dental implants, clear aligners, and innovative digital dental software based in Salon-de-Provence, France. The transaction was announced on December 16, 2022.
Biotech Dental has several important solutions, including Nemotec, a comprehensive, integrated suite of planning and diagnostic software using open architecture that connects disparate medical devices to create a digital view of the patient, offering greater diagnostic accuracy and an improved patient experience. Biotech Dental is also one of the fastest-growing manufacturers in France of custom abutments and implants, under the Kontact brand, and of clear aligners, under the Smilers brand. In addition, Biotech Dental has launched LaGalaxy, a comprehensive, open, and secure software platform where both clinical and administrative tasks can be performed. Within a single platform, dentists and dental laboratories benefit from end-to-end integrated digital solutions that help improve case outcomes while speeding treatment time, shortening case completion, and lowering the costs of implants, orthodontic, and prosthetic treatments. Henry Schein and Biotech Dental are mutually invested in the growth of these businesses and the Biotech Dental brand globally.
Philippe Veran, Biotech Dental Founder and President, will continue to lead the business, supported by Dr. Olivia Veran, a dental surgeon who is Biotech Dental’s Senior Vice President and Managing Director. Biotech Dental will maintain its own brands and go-to-market strategies. Mr. Veran will work closely with Henry Schein’s management team to advance the growth of the Company’s software, implant, and orthodontics businesses globally.
As part of the transaction, Mr. and Dr. Veran will also become minority partners in Henry Schein Orthodontics. This alignment enables Henry Schein and Biotech Dental to offer a best-in-class, comprehensive set of orthodontic solutions to its combined customer base, including software, aligners, and traditional orthodontic appliances.
“We are very pleased to complete our partnership with Henry Schein, a company that shares our commitment to provide dentists, orthodontists, and dental laboratories with the specialized tools they need to provide quality care to their patients,” said Mr. Veran. “This investment marks a new chapter for our customers, who will benefit from the innovation and new technologies we will bring to the global dental community as well as access to a wide array of products and services available through Henry Schein.”
Under the terms of the transaction, Henry Schein acquired a majority ownership position in Biotech Dental. Upperside Capital Partners Group will continue to own the remaining minority interest in the company. For the fiscal year 2022, Biotech Dental’s revenue was approximately $100 million. Henry Schein expects this transaction to be slightly dilutive to 2023 earnings per share when excluding amortization expense primarily due to non-cash acquisition accounting adjustments for inventory. Financial terms were not disclosed.
Source: Company Press Release
